Brian Lewis, MD
Internal Medicine · New Orleans, LANPI 1871773705
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.
Across 41 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$174
- Novartis$106
- Sanofi-aventis U.S. LLC$100
- Gilead$93
- Sanofi$66
- Pfizer$64
- plus $397 from 13 others
Across 177 payments — averaging $11,145 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.4M
- E.r. Squibb & Sons, L.L.C.$219K
- Merck$181K
- AVEO Pharmaceuticals, Inc.$173K
- Genentech, Inc.$12K
- Janssen Research & Development, LLC$9K
- plus $23K from 6 others
What the payments were for
- Food & beverage$90090%
- Education$10010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 8 | $174 |
| Novartis | 4 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Gilead | 4 | $93 |
| Sanofi | 3 | $66 |
| Pfizer | 3 | $64 |
| Merck | 2 | $62 |
| Daiichi Sankyo Inc. | 2 | $57 |
| Eisai Inc. | 2 | $44 |
| Bristol Myers Squibb | 2 | $32 |
| Exelixis Inc. | 2 | $31 |
| AVEO Pharmaceuticals, Inc. | 1 | $28 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Clovis Oncology, Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $22 |
| Myovant Sciences Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $17 |
| Dendreon Pharmaceuticals LLC | 1 | $14 |
How this compares
$1,000 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 67 | $899,197 |
| InlytaAxitinib | 29 | $622,682 |
| Abiraterone Acetate | 215 | $517,615 |
| CabometyxCabozantinib S-Malate | 11 | $279,123 |
| ErleadaApalutamide | 13 | $194,130 |
| OrgovyxRelugolix | 29 | $77,941 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $753 |
| Prednisone | 139 | $586 |
| Dexamethasone | 48 | $387 |
| Tamsulosin Hcl | 14 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $174 | $899,19767 claims |
| PfizerInlyta | $64 | $622,68229 claims |
| Exelixis Inc.Cabometyx | $31 | $279,12311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in New Orleans
- Steven DeitelzweigNew Orleans$939K
- Daniel EnglertNew Orleans$74K
- Jordan GrahamNew Orleans$25K
- Pavan ChavaNew Orleans$24K
- Susan KaramNew Orleans$22K
- Arti ThanguduNew Orleans$20K
- David BrownNew Orleans$17K
- Peter PantlinNew Orleans$13K
- Genevieve MarongeNew Orleans$12K
- Samiullah ArshadNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.